Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs STMicroelectronics NV (STM) Price & Performance

Merck & Co., Inc.Trade
STMicroelectronics NVTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs STMicroelectronics NV — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while STMicroelectronics NV trades at $52.06 (market cap $48.14B). The key difference: Merck & Co., Inc. is far larger — about 7.3× STMicroelectronics NV's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and STMicroelectronics NV for 64 Days on average.

MRKSTM
Market Cap
$351.28B$48.14B
Volume
7,969,6659,776,015
Sector
HealthTechnology
52-Week High
$156.43$79.91
52-Week Low
$82.49$21.20
Typical Hold Time
98 Days64 Days
Enterprise Value
$398.04B$45.66B
Dividend Yield
2.39%0.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.

The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.

STMicroelectronics NV

STM trades at $52.71, down 6.18% on the day, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS beat ($0.31 vs. $0.26 expected) but missed in Q4 2025 and Q1 2026. Revenue declined from $16.1B in 2022 to $11.8B in 2025, with net income margin turning negative at -0.39% in 2026. Analyst consensus remains positive with a $77.31 price target (51.72% buy ratings), supported by strong AI data-center revenue projections exceeding $2B by 2027 (Reuters, 2026-09-09).

STM faces near-term profitability challenges but offers long-term growth potential in AI and automotive semiconductors. Key risks include execution on margin recovery and macroeconomic volatility. The stock trades at a premium P/E of 101.49, requiring sustained earnings acceleration to justify valuation. Institutional sentiment is cautiously optimistic given the 46% upside to consensus target.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRK
60% Buy40% Sell
Avg holding period · 98 Days
STM
100% Buy0% Sell
Avg holding period · 64 Days

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →

About STMicroelectronics NV

A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.

Read more on STM →